Deletion of Srf affects key signaling pathways
| Down-regulated genes . | Up-Regulated genes . | ||
|---|---|---|---|
| Pathways . | Genes . | Pathways . | Genes . |
| Regulation of actin cytoskeleton | ACTB, ITGAL, SSH1, SSH2, PIK3CD, WASF2, RAF1, ACTN1, PIP5K1A, MYH9, IQGAP1, ACTG1, CHRM3, ITGA8, SOS2, PPP1R12A, FGD3, DIAP1, PIK3R2, MYH10 | Natural killer cell mediated cytotoxicity | PRF1, KLRA18, KLRK1, KLRA33, GZMB, NCR1, LAT, SH2D1A, KLRA9, KLRA8, IFNG, KLRA4, KLRA7, FASL, KLRD1, KLRB1C, KLRC1 |
| Jak-STAT signaling pathway | IL9R, SOCS3, IL4RA, CREBBP, PIK3CD, STAT5B, CBL, IL6RA, AKT1, PIAS4, SOS2, JAK1, CSF2RB, CSF3R, IL13RA1, PIK3R2 | Cytokine-cytokine receptor interaction | IL2RB, IL1R1, CXCL9, CCL8, PF4, CCL5, KDR, TNFSF8, CCR9, VEGFC, TNFRSF9, CXCL16, IFNG, PDGFC, EPOR, FASL, XCL1, MPL |
| MAPK signaling pathway | IL1R2, TGFBR2, MAP4K2, RAF1, MKNK1, HSPA1A, SRF, FLNA, AKT1, FOS, MAP4K4, RPS6KA3, CASP3, DUSP1, MAP3K3, ARRB1, RASGRP4, RPS6KA2, JUN, SOS2, IL1B, MAP3K14 | Graft-versus-host disease | PRF1, KLRA9, KLRA8, IFNG, KLRA7, GZMB, FASL, KLRD1, KLRC1, CD28 |
| Focal adhesion | ACTB, TLN1, PIK3CD, RAF1, ACTN1, HGF, FLNA, ACTG1, AKT1, ITGA8, JUN, SOS2, PPP1R12A, ZYX, THBS1, COL11A2, DIAP1, PIK3R2 | Hematopoietic cell lineage | IL1R1, GP5, CD3G, CD8A, CD3E, CD59A, CD4, ANPEP, EPOR, CD5 |
| Toll-like receptor signaling pathway | AKT1, FOS, CD80, JUN, PIK3CD, TLR2, IL1B, TLR4, TLR5, TLR6, TLR8, PIK3R2 | T cell receptor signaling pathway | PRKCQ, LAT, CD3G, CD8A, CD3E, ICOS, IFNG, CTLA4, CD4, PDCD1, CD28 |
| Renal cell carcinoma | AKT1, HIF1A, JUN, SOS2, PIK3CD, CREBBP, SLC2A1, RAF1, HGF, PIK3R2 | Cell adhesion molecules (CAMs) | CADM1, CD8A, ICOS, CTLA4, CD4, ESAM, CD226, PDCD1, SDC3, CD28 |
| Acute myeloid leukemia | AKT1, PPARD, SOS2, STAT5B, PIK3CD, RAF1, RARA, ZBTB16, PIK3R2 | Complement and coagulation cascades | VWF, C3AR1, HC, C4B, CD59A, C2, F2R |
| Cytokine-cytokine receptor interaction | IL1R2, IL18RAP, IL9R, CCR1, IL4RA, TGFBR2, BMPR2, CXCR1, CXCR2, TNFRSF14, HGF, IL17RA, IL6RA, CCL6, INHBA, IL1B, CSF3R, CSF2RB, IL13RA1, LTB | Vascular smooth muscle contraction | PRKCQ, ADORA2A, MYLK3, CALD1, ADCY6, MRVI1, GUCY1A3, GUCY1B3 |
| Pathways in cancer | DVL2, PPARD, PTGS2, TGFBR2, CREBBP, PIK3CD, STAT5B, CBL, RAF1, HGF, ZBTB16, AKT1, FOS, CASP3, HIF1A, PIAS4, JUN, SLC2A1, SOS2, JAK1, CSF3R, RARA, TRAF5, PIK3R2 | Chemokine signaling pathway | CCR9, CXCL16, ADCY6, CXCL9, CCL8, PF4, GNG11, XCL1, CCL5 |
| Down-regulated genes . | Up-Regulated genes . | ||
|---|---|---|---|
| Pathways . | Genes . | Pathways . | Genes . |
| Regulation of actin cytoskeleton | ACTB, ITGAL, SSH1, SSH2, PIK3CD, WASF2, RAF1, ACTN1, PIP5K1A, MYH9, IQGAP1, ACTG1, CHRM3, ITGA8, SOS2, PPP1R12A, FGD3, DIAP1, PIK3R2, MYH10 | Natural killer cell mediated cytotoxicity | PRF1, KLRA18, KLRK1, KLRA33, GZMB, NCR1, LAT, SH2D1A, KLRA9, KLRA8, IFNG, KLRA4, KLRA7, FASL, KLRD1, KLRB1C, KLRC1 |
| Jak-STAT signaling pathway | IL9R, SOCS3, IL4RA, CREBBP, PIK3CD, STAT5B, CBL, IL6RA, AKT1, PIAS4, SOS2, JAK1, CSF2RB, CSF3R, IL13RA1, PIK3R2 | Cytokine-cytokine receptor interaction | IL2RB, IL1R1, CXCL9, CCL8, PF4, CCL5, KDR, TNFSF8, CCR9, VEGFC, TNFRSF9, CXCL16, IFNG, PDGFC, EPOR, FASL, XCL1, MPL |
| MAPK signaling pathway | IL1R2, TGFBR2, MAP4K2, RAF1, MKNK1, HSPA1A, SRF, FLNA, AKT1, FOS, MAP4K4, RPS6KA3, CASP3, DUSP1, MAP3K3, ARRB1, RASGRP4, RPS6KA2, JUN, SOS2, IL1B, MAP3K14 | Graft-versus-host disease | PRF1, KLRA9, KLRA8, IFNG, KLRA7, GZMB, FASL, KLRD1, KLRC1, CD28 |
| Focal adhesion | ACTB, TLN1, PIK3CD, RAF1, ACTN1, HGF, FLNA, ACTG1, AKT1, ITGA8, JUN, SOS2, PPP1R12A, ZYX, THBS1, COL11A2, DIAP1, PIK3R2 | Hematopoietic cell lineage | IL1R1, GP5, CD3G, CD8A, CD3E, CD59A, CD4, ANPEP, EPOR, CD5 |
| Toll-like receptor signaling pathway | AKT1, FOS, CD80, JUN, PIK3CD, TLR2, IL1B, TLR4, TLR5, TLR6, TLR8, PIK3R2 | T cell receptor signaling pathway | PRKCQ, LAT, CD3G, CD8A, CD3E, ICOS, IFNG, CTLA4, CD4, PDCD1, CD28 |
| Renal cell carcinoma | AKT1, HIF1A, JUN, SOS2, PIK3CD, CREBBP, SLC2A1, RAF1, HGF, PIK3R2 | Cell adhesion molecules (CAMs) | CADM1, CD8A, ICOS, CTLA4, CD4, ESAM, CD226, PDCD1, SDC3, CD28 |
| Acute myeloid leukemia | AKT1, PPARD, SOS2, STAT5B, PIK3CD, RAF1, RARA, ZBTB16, PIK3R2 | Complement and coagulation cascades | VWF, C3AR1, HC, C4B, CD59A, C2, F2R |
| Cytokine-cytokine receptor interaction | IL1R2, IL18RAP, IL9R, CCR1, IL4RA, TGFBR2, BMPR2, CXCR1, CXCR2, TNFRSF14, HGF, IL17RA, IL6RA, CCL6, INHBA, IL1B, CSF3R, CSF2RB, IL13RA1, LTB | Vascular smooth muscle contraction | PRKCQ, ADORA2A, MYLK3, CALD1, ADCY6, MRVI1, GUCY1A3, GUCY1B3 |
| Pathways in cancer | DVL2, PPARD, PTGS2, TGFBR2, CREBBP, PIK3CD, STAT5B, CBL, RAF1, HGF, ZBTB16, AKT1, FOS, CASP3, HIF1A, PIAS4, JUN, SLC2A1, SOS2, JAK1, CSF3R, RARA, TRAF5, PIK3R2 | Chemokine signaling pathway | CCR9, CXCL16, ADCY6, CXCL9, CCL8, PF4, GNG11, XCL1, CCL5 |